Viking Therapeutics VKTX Operating Leases Interest Expense
Operating Leases Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept vktx:OperatingLeasesInterestExpense.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's operating leases interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's operating leases interest expense?
- Viking Therapeutics (VKTX) reported operating leases interest expense of $1K in Q1 2026.
- How has Viking Therapeutics's operating leases interest expense changed year-over-year?
- Viking Therapeutics's operating leases interest expense decreased by 90.0% year-over-year, from $10K to $1K.
- What is the long-term trend for Viking Therapeutics's operating leases interest expense?
- Over 3 years (2021 to 2024), Viking Therapeutics's operating leases interest expense has grown at a 51.2% compound annual growth rate (CAGR), from $11K to $38K.
- What does operating leases interest expense mean?
- This represents the portion of operating lease payments that is classified as interest expense under current accounting standards. It isolates the financing component of lease obligations from the total lease payment. This helps analysts distinguish between the operational cost of using an asset and the cost of financing that asset.